 Key highlights 
 
 
Provexis plc Annual report and accounts 2011        2 
 
 
 
 
Key highlights 
 
 The Company has entered into a conditional agreement to acquire SiS (Science in Sport) Limited for a 
consideration of £8m, partially funded by a £2.5m conditional placing at 1.5p per share, which is 
expected to complete on 24 June 2011.  
 
 Good progress to commercialise Fruitflow® heart-health technology in all major global markets under the 
Alliance Agreement with DSM Nutritional Products. 
 
 Clinical trial for NSP#3G for Crohn‟s disease patients progressed through interim review with focus now 
on opening new trial centres to complete patient recruitment.  
 
 Collaboration with Institute of Food Research for the reduction of cardiovascular inflammation and the 
reduction of risk of certain cancers making good progress with the first human trials underway. 
 
 Agreement entered into with DSM Nutritional Products to develop technology for management of blood 
glucose.  
 
 £2.5m total funding raised through Equity Financing Facility in June 2010 and October 2010. 
 
 
Key financial results 
 
 Loss attributable to owners of the parent for the year ended 31 March 2011 £2.0m (2010: £1.6m). 
 
 Cash balance as at 31 March 2011 £7.6m (2010: £7.0m). 
 
 Loss per share for the year ended 31 March 2011 0.17p (2010: 0.18p). 
 
 
